DeCure for Noonan syndrome with multiple lentigines
DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Noonan syndrome with multiple lentigines — screening already-approved drugs against its 6-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleNoonan syndrome with multiple lentigines maps to a 6-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for noonan syndrome with multiple lentigines is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
protein tyrosine phosphatase non-receptor type 11 (PTPN11) — PTPN11 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet pgedrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4GWF · 2.1 Å · ligand TRIETHYLENE GLYCOL (PGE). Experimental structure, not a prediction.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
International Journal of Science and Research (IJSR) · 2023 · 0 citations · open access
Multiple Lentigines Syndrome: A Rare Case of Noonan Related Syndrome
AbstractWe report a rare case of an 8 -year -oldmale with features of short stature, hypertelorism, low set ears, hypertrophic cardiomyopathy suggestive of Noonan syndrome.Noonan syndrome is an autosomal dominant disorder resulting in mutations in genes involved in the RAS -MAPKpathway.On examination of our patient, he was found to have multiple lentigines throughout the body along with features such as ECG abnormalities, cryptorchidism and sensorineural deafness.These features are found in LEOPARD syndrome which is a Noonan related syndrome, which are characterised by overlapping phenotypes with Noonan syndrome.LEOPARD syndrome is now known as Multiple lentigines syndrome.
Clinical and Experimental Dermatology · 2024 · 0 citations
A novel variant in <i>PTPN11</i>, c.1277A&gt;G p.(His426Arg), in a patient with Noonan syndrome with multiple lentigines
AbstractNoonan syndrome with multiple lentigines (NSML) is a rare autosomal dominant condition arising from gene variants involved in the RAS-MAPK pathway. The presence of multiple skin cancers is not widely reported in NSML. We report on a novel missense variant causing NSML in a patient with an unusual distribution of lentigines and multiple skin cancers. An increased awareness of the potential for malignant change of lentigines in NSML may encourage regular skin surveillance as a mainstay of multidisciplinary management, enabling early diagnosis and management of skin cancers in this group of patients.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
